中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1331 records (took 0.051 seconds)

    MITOCHONDRIAL PNA PROSTATE CANCER MARKER AND RELATED SYSTEMS AND METHODS
    51.
    发明申请
    MITOCHONDRIAL PNA PROSTATE CANCER MARKER AND RELATED SYSTEMS AND METHODS 审中-公开
    线粒体PNA前列腺癌标记物及相关系统和方法

    公开(公告)号：WO2017205963A1

    公开(公告)日：2017-12-07

    申请号：PCT/CA2017/000139

    申请日：2017-06-02

    Applicant: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) ,  UNIVERSITY HEALTH NETWORK

    Inventor： HOPKINS, Julia A. ,  BOUTROS, Paul ,  BRISTOW, Robert G.

    IPC: C12Q1/68 ,  G01N33/48 ,  G06F19/22

    CPC classification number: C12Q1/6886 ,  C12Q1/6881 ,  C12Q2600/118 ,  C12Q2600/156 ,  G01N33/57434 ,  G16H50/20 ,  G16H50/30

    Abstract: There is described herein a method of prognosing and/or predicting disease progression and/or in subject with prostate cancer, the method comprising: a) providing a sample containing mitochondrial genetic material from prostate cancer cells; b) sequencing the mitochondrial genetic material with respect to at least 1 patient biomarker selected from CSB1, OHR, ATP8 and HV1 (hypervariable region 1); c) comparing the sequence of said patient biomarkers to control or reference biomarkers to determine mitochondrial single nucleotide variations (mtSNVs); and d) determining the a prostate cancer prognosis; wherein a relatively worse outcome is associated with the presence of mtSNVs in CSB1, OHR, ATP8 and a relatively better outcome is associated with the presence of mtSNVs in HV1.

    Abstract translation: 本文描述了预测和/或预测疾病进展和/或患有前列腺癌的受试者中的方法，所述方法包括：a）提供含有来自前列腺癌细胞的线粒体遗传物质的样品; b）相对于选自CSB1，OHR，ATP8和HV1（高变区1）的至少一种患者生物标志物对线粒体遗传物质进行测序; c）比较所述患者生物标志物的序列与对照或参照生物标志物以确定线粒体单核苷酸变异（mtSNV）; 和d）确定前列腺癌预后; 其中相对较差的结果与CSB1，OHR，ATP8中mtSNV的存在相关并且相对较好的结果与HV1中mtSNV的存在相关。

    PEPT1DE-HLA COMPLEXES AND METHODS OF PRODUCING SAME
    53.
    发明申请
    PEPT1DE-HLA COMPLEXES AND METHODS OF PRODUCING SAME 审中-公开

    公开(公告)号：WO2017185169A8

    公开(公告)日：2017-11-02

    申请号：PCT/CA2017/000102

    申请日：2017-04-27

    Applicant: UNIVERSITY HEALTH NETWORK (UHN)

    Inventor： HIRANO, Naoto ,  NAKATSUGAWA, Munehide ,  RAHMAN, Muhammed Aashiq ,  MURATA, Kenji

    IPC: C07K14/74 ,  C12N15/12 ,  C12N5/10 ,  G01N33/53 ,  G01N33/569

    Abstract: There is provided herein, the use of mammalian derived HLA class I molecule for in vitro peptide exchange. For example, there is provided a method of producing an HLA class I molecule complexed to a pre-selected peptide comprising: (a) providing a mammalian derived HLA class 1 molecule complexed to an existing peptide; (b) incubating, in vitro, the HLA class I molecule complexed to the existing peptide with the pre-selected peptide, wherein the pre-selected peptide is at a concentration sufficient to replace the existing peptide to produce the HLA class I molecule complexed to the pre-selected peptide; and the HLA class I molecule comprises a1, a1, a2, a3 and β2m domains.

    METHODS, COMPOUNDS AND COMPOSITIONS FOR MODULATING BLOOD BRAIN BARRIER INTEGRITY AND RE-MYELINATION
    54.
    发明申请
    METHODS, COMPOUNDS AND COMPOSITIONS FOR MODULATING BLOOD BRAIN BARRIER INTEGRITY AND RE-MYELINATION 审中-公开
    方法，化合物和组合物，用于调节血液脑阻滞剂的完整性和再释放

    公开(公告)号：WO2017049411A1

    公开(公告)日：2017-03-30

    申请号：PCT/CA2016/051122

    申请日：2016-09-23

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： MONNIER, Philippe Patrick ,  TASSEW, Nardos G. ,  BAGLAENKO, Yuriy

    IPC: A61K38/17 ,  A61K39/395 ,  A61K49/00 ,  A61P21/00 ,  A61P25/28 ,  C07K14/47

    CPC classification number: A61K38/179 ,  A61K38/1709 ,  A61K39/395 ,  C07K14/47

    Abstract: Disclosed herein are methods and compositions for increasing and decreasing the permeability of the blood brain barrier for the treatment of diseases and conditions and to facilitate the delivery of agents to the brain, as well as methods and compositions for promoting re-myelination and preventing de-myelination. Compositions include RGMa, soluble RGMa, and functional fragments and variants thereof, RGMc, soluble RGMc, and functional fragments and variants thereof, and Neogenin peptides including 4Ig.

    Abstract translation: 本文公开了用于增加和减少用于治疗疾病和病症的血脑屏障的渗透性并促进药物递送至脑的方法和组合物，以及用于促进再髓鞘化和预防脱发的方法和组合物， 髓鞘形成。 组合物包括RGMa，可溶性RGMa及其功能片段及其变体，RGMc，可溶性RGMc及其功能片段及变体，以及包含4Ig的Neogenin肽。

    SYSTEM AND METHOD FOR ENHANCED MASS SPECTROMETRY IMAGING
    58.
    发明申请
    SYSTEM AND METHOD FOR ENHANCED MASS SPECTROMETRY IMAGING 审中-公开
    用于增强大量光谱成像的系统和方法

    公开(公告)号：WO2016090471A1

    公开(公告)日：2016-06-16

    申请号：PCT/CA2015/051282

    申请日：2015-12-08

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： ZARRINE-AFSAR, Arash ,  JAFFRAY, David A.

    IPC: G01N27/00 ,  A61K51/04 ,  A61K49/00

    CPC classification number: A61K49/106 ,  A61K49/00 ,  A61K49/0438 ,  G01N27/00 ,  G01N33/4833 ,  G01N33/58 ,  G01N2458/15 ,  G01N2560/00 ,  H01J49/0004 ,  H01J49/105

    Abstract: Various embodiments are described herein for a system and a method for identifying a region of interest in tissue using mass spectrometry. An agent administration component can be provided to administer an exogenous agent to the tissue. A sampling unit can also be provided to acquire a sample from the tissue. The sample can then be provided to a high sensitivity analysis platform, such as a mass analyzer, to analyze the sample and determine a distribution of the exogenous agent or a by-product of the exogenous agent within the tissue based on the analysis. The analysis platform can then identify the region of interest based on the distribution of the exogenous agent or the distribution of the by-product.

    Abstract translation: 本文描述了用于使用质谱法鉴定组织中的感兴趣区域的系统和方法的各种实施方案。 可以提供药剂施用组分以向组织施用外源性试剂。 还可以提供采样单元以从组织获取样品。 然后将样品提供给诸如质量分析仪的高灵敏度分析平台，以分析样品并基于分析确定组织内的外源性试剂或副产物的分布。 然后，分析平台可以基于外源性代理的分布或副产物的分布来识别感兴趣的区域。

Patent Agency Ranking